Actinium Pharmaceuticalsincis A Late Stage Biopharmaceutical Company Based In New York Cityit Specializes In Targeted Radiotherapies For Cancer Treatmentfocusing On Patients With Limited Therapeutic Optionsthe Company Aims To Improve Survival Outcomes In Hematologic Malignancies And Solid Tumors Using Its Proprietary Antibody Radiation Conjugatearctechnology Actinium S Pipeline Includes Several Innovative Therapiesiomab B Is In Late Stage Development For Conditioning Prior To Bone Marrow Transplants In Patients With Relapsed Refractory Acute Myeloid Leukemiaaml Actimab A Is Another Therapy Targeting R R Amldeveloped In Collaboration With The National Cancer Institutethe Company Is Also Advancing Iomab Acta Next Generation Conditioning Agent For Cell And Gene Therapiesactinium Holds 230 Patents And Applicationsincluding Methods For Producing The Alpha Emitting Isotope Actinium 225The Company Collaborates With Leading Research Institutions To Enhance Its Clinical Development Efforts
United States
